Investment story

Cereno Scientific is a clinical-stage biotech company focusing on developing innovative, effective, and safe treatments for patients affected by common and rare cardiovascular disease where great unmet medical needs persist. Cardiovascular disease is the number one cause of death globally, killing nearly twice as many people as cancer. The term cardiovascular disease includes all diseases which involve the heart and/or the blood vessels. A majority of the complications associated with cardiovascular disease are caused by a blocking blood clot in a vein or artery in the body. Many people affected by a blood clot have as a consequence, for example, a heart attack, secondary heart failure, cardiac arrhythmias, stroke or other direct manifestations of blood clots in lungs or peripheral vessels.

Cereno's pipeline comprises:

  • Drug candidate CS1 in Phase II is being developed as a treatment of the rare disease pulmonary arterial hypertension (PAH).
  • Drug candidate CS014 in late preclinical phase is being developed as a treatment for thrombosis prevention.
  • Drug candidate CS585 in preclinical phase is being evaluated as a treatment for cardiovascular disease.

Cereno Scientific's B share (CRNO B) has been traded on Nasdaq First North Growth Market since June 2023, when a move from Spotlight Stock Market was completed where the company had been listed since June 2016.

Share capital development

Overview

Shares of series A warrant ten (10) votes per one (1) share and shares of series B warrant one (1) vote per one (1) share. The shares ratio value amounts to 0,1 SEK. All shares entitle the shareholder to equal rights to share the company’s assets and earnings.

Updated: December 2020

YearEventRatio value (SEK)Difference in sharesChange (SEK) Total number of sharesTotal share capital (SEK)
2012Formation150 00050 00050 00050 000
2012Rights issue110 60510 60560 60560 605
2016Directed issue11 2001 20061 80561 805
2016Stock dividend issue10556 24561 805618 050
2016Share split 100:10.16 118 6956 180 500618 050
2016Subdivision A-/B- shares0.106 180 500
2016Directed issue0.10 1 420 000 1 420 0007 600 500760 050
2016Directed issue0.10450 00045 0008 050 500805 050
2016IPO0.102 940 000294 00010 990 5001 099 050
2018Conversion0.10188 67918 867.9011 179 1791 117 917.90
2018Conversion0.10444 44444 444.4011 623 6231 162 362.30
2018Conversion0.10540 54054 05412 164 1631 216 416.30
2018Conversion0.10483 870483 870012 648 0331 264 803.30
2018Conversion0.10419 35441 935.4013 067 3871 306 738.70
2018Conversion0.10384 61438 461.4013 452 0011 345 200.10
2018Conversion0.10269 23026 92313 721 2311 372 123.10
2018Conversion0.10307 69230 769.2014 028 9231 402 892.30
2018Conversion0.10333 33333 333.3014 362 2561 436 225.60
2018Conversion0.10285 71428 571.4014 647 9701 464 797.00
2019Conversion0.10533 33353 333.3015 181 3031 518 130.30
2019Conversion0.10666 66666 666.6015 847 9691 584 796.90
2019Conversion0.103 333 333333 333.3019 181 3021 918 130.20
2019Rights issue0.1019 181 3021 918 130.2038 362 6043 836 260.40
2019Overallotment issue0.101 724 137172 413.7040 086 7414 008 674.10
2019Remuneration issue0.10132 57113 257.1040 219 3124 021 931.20
2020Rights issue0.131 600 0003 160 00071 819 3127 181 931.20
2021Share issue0,1033 442 4703 344 247,00105 261 78210 526 178,20

Dividend policy

Dividend policy

Cereno will continue to focus on developing and expanding the company’s pipeline. Cereno scientific have not yet paid any dividend and the companys board does not intend to propose any dividend within the next two years. Any profits will instead be reinvested in the Company’s product and business developement to finance the company’s long-term strategy. Any future dividends and the size thereof is determined based on the company’s long-term growth, earnings trend, and capital requirements, taking into account the current objectives and strategies adopted.

Largest shareholders

Share issues

Our share issues

Access information related to the company’s current and/or previous share issues. Information is in Swedish only.

Rights issue April 2023

Read more

Warrant TO1

Read more

Warrant TO2

Read more

Directed issue Sep 2020

Read more

Rights issue May 2019

Read more

IPO 2016

Read more

Analysts

Edison Investment Research

Analyst: Soo Romanoff

 

Financial reports

Financial calendar

22 May 2023

Interim report Q1 2023

1 June 2023

Annual General Meeting

25 August 2023

Interim report Q2 2023

17 November 2023

Interim report Q3 2023

22 February 2024

Interim report Q4 2023

w/c 15 April 2024

Annual Report 2023

23 May 2024

Interim report Q1 2024

28 May 2024

Annual General Meeting

29 August 2024

Interim report Q2 2024

21 November 2024

Interim report Q3 2024

25 February 2025

Year-end report 2024

Subscribe to our news

Get immediate updates, subscribe to our news.